Internal Medicine Doctors in Vernon, NJ Accepting Medicare

6 Internal Medicine doctors found. Showing 1 - 6

Dr. Kristopher Paul Korsakoff, M.D. Internal Medicine - Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 212 State Route 94, Suite 1a, Vernon, NJ 07462 Phone: 973-864-6029    Fax: 973-864-1010

Dr. Eric Samuel Hansen, D.O. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 Route 94, Suite 1-d, Vernon, NJ 07462 Phone: 973-209-2162    Fax: 973-209-2665

Dr. Min Yen Han, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 249 Rt 94, Suite 3, Vernon, NJ 07462 Phone: 973-827-3150    Fax: 973-827-5845

Pasquale J Yaccarino, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 State Rt 94 Ste 1-c, Vernon, NJ 07462 Phone: 973-823-8800    Fax: 973-823-8811

Dr. Amy Grace Geisen, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 212 State Rt 94, Suite 1c, Vernon, NJ 07462 Phone: 973-823-8800

Thomas Anthony Lanzilotti, M.D., F.A.C.C. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Route 94, Suite F, Vernon, NJ 07462 Phone: 973-827-0844    Fax: 973-827-0854

News Archive

Researchers investigate nonanalytical reasoning conditions for diagnostic errors

Silvia Mamede, M.D., Ph.D., of Erasmus University Rotterdam, the Netherlands and colleagues investigated whether recent experience with clinical problems provokes availability bias (overestimation of the likelihood of a diagnosis based on the ease with which it comes to mind) resulting in diagnostic errors and whether reflection (structured reanalysis of the case findings) counteracts this bias.

Characterizing SARS-CoV-2 convalescent plasma

A new study published on the preprint server bioRxiv in June 2020 uses serologic correlates to assess the efficacy of convalescent plasma. This will also help to classify donor plasma as more or less potent at neutralizing the virus.

Onyx enters commercialization agreement with Ono for carfilzomib and ONX 0912 development program

Onyx Pharmaceuticals, Inc. today announced that it has entered into an exclusive agreement with Ono Pharmaceutical Co., Ltd. to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib and ONX 0912. Under the terms of the agreement, Ono has exclusive rights to develop and commercialize both compounds for all oncology indications in Japan.

Appeals court to weigh challenge to health law subsidies

Opponents of the health law argue that the legislative language never says subsidies can be used to defray premium costs for low- and moderate-income people who live in states that did not set up their own online marketplaces and are served instead by the federal exchange. Also, in news about how the law is being implemented, a look at who is exempted from the mandate to get insurance.

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Cancer scientists led by Dr. John Dick at the Princess Margaret Cancer Centre have found a way to follow single tumour cells and observe their growth over time. By using special immune-deficient mice to propagate human colorectal cancer, they found that genetic mutations, regarded by many as the chief suspect driving cancer growth, are only one piece of the puzzle. The team discovered that biological factors and cell behaviour - not only genes - drive tumour growth, contributing to therapy failure and relapse.

Read more Medical News

› Verified 9 days ago